Message Testing for Tobacco-Related Corrective Statements
Status: | Completed |
---|---|
Conditions: | Smoking Cessation |
Therapuetic Areas: | Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | 14 - 17 |
Updated: | 2/7/2019 |
Start Date: | January 21, 2011 |
BACKGROUND:
This document outlines the study design and procedures to be used to evaluate a series of
corrective statements to augment consumer knowledge and beliefs about smoking as related to
past actions of tobacco companies. The statements were ordered by a U.S. Federal Court in
U.S. v. Philip Morris USA, Inc., and are intended to target potential misperceptions
resultant of past marketing and promotion practices undertaken by the tobacco industry.
OBJECTIVES:
The U.S. Department of Justice has asked NCI to take the lead on developing and testing
corrective statements with adult and youth audiences to ensure both message comprehension and
avoidance of unintended consequences of message exposure, such as boomerang effects, smoking
triggers, or knowledge gaps.
The court has identified five areas that the statements shall address:
1. The adverse health effects of smoking;
2. The addictiveness of smoking and nicotine;
3. The lack of any significant health benefit from smoking low tar, light, ultra light,
mild, and natural cigarettes;
4. The tobacco industry s manipulation of cigarette design and composition to ensure
optimum nicotine delivery;
5. The adverse health effects of secondhand smoke.
ELIGIBILITY:
Message testing will be undertaken with the following audiences:
- Current smokers (with an oversample of low socioeconomic status individuals)
- General population nonsmokers and former smokers (with an oversample of low
socioeconomic status individuals)
- Spanish-speaking Hispanics
- Youth age 14-17
DESIGN:
Both qualitative and quantitative methods (focus groups and post-test comparison group
Web-enabled surveys) will be used to develop and test a range of corrective statements in the
five areas outlined by the court.
- Focus group participants: 48-64
- Survey participants: 2500
This document outlines the study design and procedures to be used to evaluate a series of
corrective statements to augment consumer knowledge and beliefs about smoking as related to
past actions of tobacco companies. The statements were ordered by a U.S. Federal Court in
U.S. v. Philip Morris USA, Inc., and are intended to target potential misperceptions
resultant of past marketing and promotion practices undertaken by the tobacco industry.
OBJECTIVES:
The U.S. Department of Justice has asked NCI to take the lead on developing and testing
corrective statements with adult and youth audiences to ensure both message comprehension and
avoidance of unintended consequences of message exposure, such as boomerang effects, smoking
triggers, or knowledge gaps.
The court has identified five areas that the statements shall address:
1. The adverse health effects of smoking;
2. The addictiveness of smoking and nicotine;
3. The lack of any significant health benefit from smoking low tar, light, ultra light,
mild, and natural cigarettes;
4. The tobacco industry s manipulation of cigarette design and composition to ensure
optimum nicotine delivery;
5. The adverse health effects of secondhand smoke.
ELIGIBILITY:
Message testing will be undertaken with the following audiences:
- Current smokers (with an oversample of low socioeconomic status individuals)
- General population nonsmokers and former smokers (with an oversample of low
socioeconomic status individuals)
- Spanish-speaking Hispanics
- Youth age 14-17
DESIGN:
Both qualitative and quantitative methods (focus groups and post-test comparison group
Web-enabled surveys) will be used to develop and test a range of corrective statements in the
five areas outlined by the court.
- Focus group participants: 48-64
- Survey participants: 2500
BACKGROUND:
This document outlines the study design and procedures to be used to evaluate a series of
corrective statements to augment consumer knowledge and beliefs about smoking as related to
past actions of tobacco companies. The statements were ordered by a U.S. Federal Court in
U.S. v. Philip Morris USA, Inc., and are intended to target potential misperceptions
resultant of past marketing and promotion practices undertaken by the tobacco industry.
OBJECTIVES:
The U.S. Department of Justice has asked NCI to take the lead on developing and testing
corrective statements with adult and youth audiences to ensure both message comprehension and
avoidance of unintended consequences of message exposure, such as boomerang effects, smoking
triggers, or knowledge gaps.
The court has identified five areas that the statements shall address:
1. The adverse health effects of smoking;
2. The addictiveness of smoking and nicotine;
3. The lack of any significant health benefit from smoking low tar, light, ultra light,
mild, and natural cigarettes;
4. The tobacco industry s manipulation of cigarette design and composition to ensure
optimum nicotine delivery;
5. The adverse health effects of secondhand smoke.
ELIGIBILITY:
Message testing will be undertaken with the following audiences:
- Current smokers (with an oversample of low socioeconomic status individuals)
- General population nonsmokers and former smokers (with an oversample of low
socioeconomic status individuals)
- Spanish-speaking Hispanics
- Youth age 14-17
DESIGN:
Both qualitative and quantitative methods (focus groups and post-test comparison group
Web-enabled surveys) will be used to develop and test a range of corrective statements in the
five areas outlined by the court.
- Focus group participants: 48-64
- Survey participants: 2500
This document outlines the study design and procedures to be used to evaluate a series of
corrective statements to augment consumer knowledge and beliefs about smoking as related to
past actions of tobacco companies. The statements were ordered by a U.S. Federal Court in
U.S. v. Philip Morris USA, Inc., and are intended to target potential misperceptions
resultant of past marketing and promotion practices undertaken by the tobacco industry.
OBJECTIVES:
The U.S. Department of Justice has asked NCI to take the lead on developing and testing
corrective statements with adult and youth audiences to ensure both message comprehension and
avoidance of unintended consequences of message exposure, such as boomerang effects, smoking
triggers, or knowledge gaps.
The court has identified five areas that the statements shall address:
1. The adverse health effects of smoking;
2. The addictiveness of smoking and nicotine;
3. The lack of any significant health benefit from smoking low tar, light, ultra light,
mild, and natural cigarettes;
4. The tobacco industry s manipulation of cigarette design and composition to ensure
optimum nicotine delivery;
5. The adverse health effects of secondhand smoke.
ELIGIBILITY:
Message testing will be undertaken with the following audiences:
- Current smokers (with an oversample of low socioeconomic status individuals)
- General population nonsmokers and former smokers (with an oversample of low
socioeconomic status individuals)
- Spanish-speaking Hispanics
- Youth age 14-17
DESIGN:
Both qualitative and quantitative methods (focus groups and post-test comparison group
Web-enabled surveys) will be used to develop and test a range of corrective statements in the
five areas outlined by the court.
- Focus group participants: 48-64
- Survey participants: 2500
- INCLUSION CRITERIA:
- Youth age 14-17
- Youth current smokers, former smokers, and never smokers
- Youth male and female genders
- Youth of all race/ethnicity categories, including: White, Black/African American,
Asian, Hispanic/Latino, American Indian/Alaskan Native, Native Hawaiian/Pacific
Islander
EXCLUSION CRITERIA:
Participants will be excluded from focus groups and survey if they work in:
- Media
- Advertising, market research
- Public health or health promotion
- An employee of the Federal Govemment who works at HHS or DoJ
- The tobacco or alcohol industries
We found this trial at
1
site
9609 Medical Center Drive
Bethesda, Maryland 20892
Bethesda, Maryland 20892
1-800-422-6237
National Cancer Institute , 9000 Rockville Pike The National Cancer Institute (NCI) is part of...
Click here to add this to my saved trials